1
|
Sun F, Bedenkov A, Liu BC, Yang J, Xu JF, Ji L, Zhou M, Zhang S, Li X, Song Y, Chen P, Moreno C. Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings. Pharmaceut Med 2024:10.1007/s40290-024-00520-3. [PMID: 38573457 DOI: 10.1007/s40290-024-00520-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/03/2024] [Indexed: 04/05/2024]
Abstract
Use of real-world data (RWD) is gaining wide attention. To bridge the gap between diverse healthcare stakeholders and to leverage the impact of Chinese real-world evidence (RWE) globally, a multi-stakeholder External Advisory Committee (EAC) and EAC meetings were initiated, aiming to elucidate the current and evolving RWD landscape in China, articulate the values of RWE in ensuring Chinese patients' equitable access to affordable medicines and solutions, and identify strategic opportunities and partnerships for expansion of RWE generation in China. Chinese and international experts who are clinicians and academic researchers were selected as EAC members based on their professional background and familiarity with RWD/RWE. Three EAC meetings were held quarterly in 2023. Various topics were presented and discussed for insights and suggestions. Nine experts from China, one from South Korea, and two from Europe were selected as EAC members and attended these meetings. Experts' presentations were summarized by theme, including the RWD landscape and RWE enablement in China, as well as global development of a patient-centric ecosystem. Experts' insights and suggestions on maximizing the RWD/RWE value to accelerate healthcare transformation in China were collected. We concluded that though data access, sharing, and quality are still challenging, RWD is developing to support evidence generation in the medicinal product lifecycle, inform clinical practice, and empower patient management in China. RWD/RWE creates value, accelerates healthcare transformation, and improves patient outcomes. Fostering a patient-centric ecosystem across healthcare stakeholders and maintaining global partnerships and collaboration are essential for unlocking the power of RWD/RWE.
Collapse
Affiliation(s)
- Feng Sun
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- Key Laboratory of Epidemiology of Major Diseases, Peking University, Beijing, China
| | | | - Bi-Cheng Liu
- Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine, Nanjing, China
| | - Jiefu Yang
- Department of Cardiology, Beijing Hospital, Beijing, China
| | - Jin-Fu Xu
- Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
| | - Linong Ji
- Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Center, Beijing, China
| | - Min Zhou
- Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Shaosen Zhang
- Global Evidence Powerhub China, AstraZeneca, Shanghai, China
| | - Xinli Li
- Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Yuanlin Song
- Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Pingyan Chen
- Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China.
- Hainan Institute of Real-World Data, Qionghai, China.
| | - Carmen Moreno
- Global Evidence Powerhub China, AstraZeneca, Shanghai, China.
| |
Collapse
|
2
|
Larsen K, Walton RN, Elsayed M, Ipatov A, Townsend-Holyoake F, Axelsson SFA, Quinones N, Papsch R, Givens J, Bedenkov A, Seewald M. A blueprint for success in real-world evidence: "glocal" approach to building capabilities and generating impactful evidence. Front Pharmacol 2023; 14:1233617. [PMID: 37886128 PMCID: PMC10598715 DOI: 10.3389/fphar.2023.1233617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Accepted: 09/27/2023] [Indexed: 10/28/2023] Open
Abstract
The past decade has seen the increasing influence and relevance of real-world data (RWD) and real-world evidence (RWE) in healthcare decision making. The value added by RWD/RWE has prompted the pharmaceutical industry to develop high performing systems and practices to harness the power of evidence generated at the global level. However, this worldwide transformation provides outstanding opportunities to support capability building within local affiliates and to impact key country-level stakeholders through resulting evidence. Therefore, we present an Evidence Blueprint Initiative, which links the global and local ("glocal") skills, and furthermore addresses the opportunities and gaps in evidence generation capabilities at the local level. Cross-functional experts were recruited at the local, regional, and global level to define best practices. A framework was developed to characterize the foundational expertise needed and to assess markets' existing capabilities. Subsequently, targeted roadmaps were developed and implemented to build capabilities in specific areas within each affiliate. The impact from the Blueprint is encouraging, resulting in improved local evidence plans, established evidence teams, enhanced RWD use and strategic implementation of patient centric science in local affiliates. The success of the Blueprint resides in empowering affiliates to realise their local evidence generation ambitions and to match them to their local context. It strengthens and expands the ties between various parts of the organisation and the external environment while building fit-for-future evidence capabilities from local affiliates.
Collapse
Affiliation(s)
| | - Ryan N. Walton
- AstraZeneca Medical, Europe and Canada Region, Baar, Switzerland
| | - Mohamed Elsayed
- AstraZeneca Medical, International Region, Dubai, United Arab Emirates
| | - Andrey Ipatov
- AstraZeneca Medical, International Region, Moscow, Russia
| | | | | | - Nacho Quinones
- IQVIA, EMEA Real World Solutions, Medical Evidence Practice, London, United Kingdom
| | - Rudiger Papsch
- IQVIA, EMEA Real World Solutions, Medical Evidence Practice, London, United Kingdom
| | - Jennifer Givens
- AstraZeneca Medical, Global, Gaithersburg, MD, United States
| | | | | |
Collapse
|
3
|
Bedenkov A, Rajadhyaksha V, Moreno C, Goncalves S, Fong PC, Ipatov A, Erdal B. The 7+ Habits of Highly Effective Medical Directors. Pharmaceut Med 2021; 35:267-279. [PMID: 34541619 PMCID: PMC8492585 DOI: 10.1007/s40290-021-00403-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/24/2021] [Indexed: 12/30/2022]
Abstract
Medical Directors in the pharmaceutical industry are responsible for fulfilling multiple roles, including scientific expert, conscience keeper and people leader, as well as being the external face of the organisation. The capabilities described in the book The 7 Habits of Highly Effective People® are not just the integral qualities of a successful leader, they are important capabilities that are critical to becoming an impactful medical leader too. As scientific, functional and enterprise leaders, country and cluster Medical Directors must possess these seven qualities. Each of the seven habits can be adapted and utilised to shape the specific areas that Medical Directors are responsible for: intuitive creativity, patient centricity, prioritisation, enterprise leadership, communication and behavioural change, building a team, partnering and scientific and technological leadership. To excel in their function, current and future Medical Directors need to sharpen their existing skills and build specific capabilities. Energy management in physical, mental, emotional and spiritual domains is the way forward.
Collapse
Affiliation(s)
| | | | - Carmen Moreno
- AstraZeneca Medical, International Region, Madrid, Spain
| | - Susana Goncalves
- AstraZeneca Medical, International Region, Buenos Aires, Argentina
| | - Pei-Chieh Fong
- AstraZeneca Medical, International Region, Taipei, Taiwan
| | - Andrey Ipatov
- AstraZeneca Medical, International Region, Moscow, Russian Federation
| | - Berin Erdal
- AstraZeneca Human Resources, International Region, Luton, UK
| |
Collapse
|
4
|
Bedenkov A, Moreno C, Agustin L, Jain N, Newman A, Feng L, Kostello G. Customer Centricity in Medical Affairs Needs Human-centric Artificial Intelligence. Pharmaceut Med 2021; 35:21-29. [PMID: 33464482 PMCID: PMC7814264 DOI: 10.1007/s40290-020-00378-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/27/2020] [Indexed: 12/15/2022]
Abstract
The evolution of healthcare, together with the changing behaviour of healthcare professionals, means that medical affairs functions of pharmaceutical organisations are constantly reinventing themselves. The emergence of digital ways of working, expedited by the COVID-19 pandemic, means that pharmaceutical–healthcare relationships are evolving to operate in an increasingly virtual world. The value of the pharmaceutical medical affairs function is dependent on understanding customers’ needs and providing the right knowledge at the right time to physicians. This requires a human-centric artificial intelligence (AI) approach for medical affairs, which allows the function to query internal and external data sets in a conversational format and receive timely, accurate and concise intelligence on their customers.
Collapse
Affiliation(s)
| | - Carmen Moreno
- AstraZeneca Medical Affairs, International Region, Madrid, Spain
| | - Lyra Agustin
- AstraZeneca Medical Affairs, International Region, Luton, UK
| | - Nipun Jain
- AstraZeneca Medical IT, International Region, Bangalore, India.
| | - Amy Newman
- AstraZeneca Global Medical Affairs, BioPharmaceutical Business, Gaithersburg, MD, USA
| | | | | |
Collapse
|
5
|
Abstract
Medical affairs has evolved over recent years from a support, to a partner, to a strategic leadership function. In the future, there will be significant changes in healthcare and pharmaceutical industries, and many of these will be due to technological advances and digitalisation. Medical affairs will be largely influenced by these developments in terms of partnerships with key stakeholders, embracing innovation and patient-centric healthcare, and demonstrating value for novel treatment options. In order to secure future success within their roles, medical affairs professionals will have to demonstrate specific capabilities founded on communications and behavioural change, business leadership acumen, knowledge acquisition and self-development, and the ability to generate real-world evidence from insights and expertise within data science and analytics. It will be our responsibility as medical affairs leaders to create this foundation for the leaders of tomorrow.
Collapse
Affiliation(s)
- Alexander Bedenkov
- AstraZeneca Medical, International Region, Horizon Place, 600 Capability Green, Luton, LU3 1LU, UK
| | - Viraj Rajadhyaksha
- AstraZeneca Medical, International Region, Horizon Place, 600 Capability Green, Luton, LU3 1LU, UK.
| | - Maarten Beekman
- AstraZeneca Medical, International Region, Horizon Place, 600 Capability Green, Luton, LU3 1LU, UK
| | - Carmen Moreno
- AstraZeneca Medical, International Region, Horizon Place, 600 Capability Green, Luton, LU3 1LU, UK
| | - Pei-Chieh Fong
- AstraZeneca Medical, International Region, Horizon Place, 600 Capability Green, Luton, LU3 1LU, UK
| | - Lyra Agustin
- AstraZeneca Medical, International Region, Horizon Place, 600 Capability Green, Luton, LU3 1LU, UK
| | - Sarah Odell
- AstraZeneca Human Resources, International Region, Cambridge, UK
| |
Collapse
|
6
|
Bedenkov A, Shpinev V, Suvorov N, Sokolov E, Riabenko E. Consolidating Russia and Eurasia Antibiotic Resistance Data for 1992-2014 Using Search Engine. Front Microbiol 2016; 7:294. [PMID: 27014217 PMCID: PMC4781829 DOI: 10.3389/fmicb.2016.00294] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2015] [Accepted: 02/23/2016] [Indexed: 12/02/2022] Open
Abstract
Background: The World Health Organization recognizes the antibiotic resistance problem as a major health threat in the twenty first century. The paper describes an effort to fight it undertaken at the verge of two industries—healthcare and Data Science. One of the major difficulties in monitoring antibiotic resistance is low availability of comprehensive research data. Our aim is to develop a nation-wide antibiotic resistance database using Internet search and data processing algorithms using Russian language publications. Materials and Methods: An interdisciplinary team built an intelligent Internet search filter to locate all publicly available research data on antibiotic resistance in Russia and Eurasia countries, extracted it, and collated it for analysis. A database was constructed using data from 850 original studies conducted at 153 locations in 12 countries between 1992 and 2014. The studies contained susceptibility and resistance rates of 156 microorganisms to 157 antibiotic drugs. Results: The applied search methodology was highly robust in that it yielded search precision of 58 vs. 20% in a typical Internet search. It allowed finding and collating within the database the following data items (among many others): publication details including title, source, date, authors, etc.; study details: time period, locations, research organization, therapy area, etc.; microorganisms and antibiotic drugs included in the study along with prevalence values of resistant and susceptible strains, and numbers of isolates. The next stage in project development will try to validate the data by matching it to major benchmark studies; in addition, a panel of experts will be convened to evaluate the outcomes. Conclusions: The work provides a supplementary tool to national surveillance systems in antibiotic resistance, and consolidates fragmented research data available for 12 countries for a period of more than 20 years.
Collapse
Affiliation(s)
| | - Vitaly Shpinev
- Medical Department, AstraZeneca Pharmaceuticals LLC Moscow, Russia
| | - Nikolay Suvorov
- Medical Department, AstraZeneca Pharmaceuticals LLC Moscow, Russia
| | | | | |
Collapse
|
7
|
Stratchounski L, Bedenkov A, Hryniewicz W, Krcmery V, Ludwig E, Semenov V. The usage of antibiotics in Russia and some countries in Eastern Europe. Int J Antimicrob Agents 2001; 18:283-6. [PMID: 11673044 DOI: 10.1016/s0924-8579(01)00381-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The patterns of antibiotic use in 1998 in Russia and some other countries in Eastern Europe (Belarus, Poland, Slovakia, Hungary) were studied. Poland, Slovakia and Hungary were "more modern" users of antibiotics, consuming new and expensive drugs. Russia and Belarus were "conservative" having a lower level of total consumption and using lesser quantities of penicillins, cephalosporins, macrolides, quinolones, carbapenems but greater amounts of aminoglycosides and chloramphenicol. It is essential for "conservative" countries to establish a national surveillance system of antibiotic consumption to monitor the development of bacterial resistance to antimicrobial agents and to monitor individual antibiotic use.
Collapse
Affiliation(s)
- L Stratchounski
- Institute of Antimicrobial Chemotherapy, State Medical Academy, P.O. Box 5, Smolensk 214019, Russia.
| | | | | | | | | | | |
Collapse
|